Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

May 21, 2009

Primary Completion Date

October 1, 2009

Study Completion Date

October 1, 2009

Conditions
Atopic Dermatitis
Interventions
DRUG

CD2027 Ointment 3 mcg/g, twice daily

Topical Ointment

DRUG

Vehicle Ointment, twice daily

Topical Ointment

Trial Locations (14)

33144

International Dermatology Research, Inc., Miami

40202

Dermatology Specialists PSC, Louisville

55432

Minnesota Clinical Study Center, Fridley

71913

Burke Pharmaceutical Research, Hot Springs

76011

Arlington Research Center, Inc., Arlington

77845

J&S Studies, Inc., College Station

78759

DermResearch Inc., Austin

80120

Colorado Medical Research Center, Inc., Denver

80501

Longmont Medical Research Network, Longmont

87106

Academic Dermatology Associates, Albuquerque

92123

Therapeutics Clinical Research, Inc., San Diego

97210

Oregon Dermatology & Research Center, Portland

97223

Oregon Medical Research Center, Portland

104609

Helendale Dermatology & Medical Spa, LLC, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY